$FXNC

First National Reports Record Q3 2026 Net Income of $6.9 Million

First National reported Q3 2026 net income of $6.9M, up from $5.6M a year earlier. Nine-month net income reached $17.5M. The company attributed growth to improved net interest margin, loan growth, and expense management. It also completed branch consolidations and sold two banking offices.

Original reporting
Published Oct 23, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
First National Reports Record Q3 2026 Net Income of $6.9 Million — source image
Decision brief

The 30-second read

$FXNCBullishLow
01

Why it matters

The earnings release confirms the bank's operational improvements and cost efficiencies, supporting a modest positive outlook.

02

Market read

Micro‑cap earnings beat with modest upside potential; relevance mainly to niche banking investors.

03

What to watch

Potential future branch consolidations could improve profitability further, but also reduce geographic coverage.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

First National Corp (FXNC) is a regional bank that recently streamlined its branch network, selling two offices and consolidating others.

Company-level read

Ticker impact

$FXNCBullishMedium confidence
Context

First National Corp reported record Q3 2026 net income of $6.9 million, a new earnings release with detailed financial metrics.

Expected impact

likely modest upside as the market prices in the earnings beat and improved net interest margin.

Evidence & confidence

The company posted higher earnings and EPS versus the prior year, indicating operational strength; however, the absolute scale is small for a micro‑cap, limiting price move magnitude.

Market effects

Positive signal for regional community banks showing earnings resilience.

Limited to the local banking market; unlikely to affect broader indices.

Minimal.

Counterpoint

The earnings beat may be outweighed by the company's small size and limited growth outlook.

Key entities

  • First National Corp

    Regional bank reporting Q3 2026 earnings.

Related articles

$FXNCMed

First National Corporation Reports SECOND Quarter 2026 FINANCIAL PERFORMANCE

FIRST NATIONAL CORP /VA/ (FXNC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First National Corporation Reports SECOND Quarter 2026 FINANCIAL PERFORMANCE STRASBURG, Va., July 29, 2026 --- First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported consolidated ne

$FXNCMed

First National Corporation Reports Second Quarter 2026 Financial Performance

First National Corporation (NASDAQ: FXNC) reported Q2 2026 net income of $5.7 million and EPS of $0.64 basic and $0.63 diluted for the quarter ended June 30, 2026. Results included net interest margin of 4.15% FTE, net interest income of $20.1 million, and a $426k credit loss provision. The company said regulatory approvals were received for a pending sale of North Carolina branches expected to close in early Q4 2026.

$LPLHighAI 8/10

LG Display (LPL) Q3 2026 Earnings Call Transcript

LG Display (LPL) reported Q3 2026 net income of KRW 755.6 billion, with operating profit margin at 4% and EBITDA at 19%. Area shipment grew 4% Q-o-Q to 3.7 million square meters, and ASP rose 16% to $1,250. OLED products accounted for 67% of revenue. The company expects Q4 shipment growth of around 10% but modest ASP increases due to market uncertainties. LG Display is focusing on OLED technology, including its next-gen FLiPP technology, to maintain competitiveness and profitability.

$RDYMed

Dr. Reddy’s Q2FY27 slides: base growth masks lenalidomide drag

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenues of ₹8,671 crores, down 1.5% YoY but up 7% sequentially. EBITDA margin was 20.6%, with profit after tax at ₹925 crores. North America sales declined 23% YoY due to lenalidomide, but other regions showed growth. The company announced strategic partnerships and product developments, including a dengue vaccine and biosimilars. Shares rose 0.45% to $13.29 post-results.